- Presentations
- 2
- Markets
- 1
Inmazeb is a brand of Atoltivimab, Maftivimab and Odesivimab marketed by Regeneron Pharmaceuticals, with 2 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Atoltivimab, Maftivimab and Odesivimab
- Brand owner
- Regeneron Pharmaceuticals
- Registered in
- United States
- Strengths and forms
- 241.7 mg/241.7 mg/241.7 mg per 14.5 mL injection, 483.3 mg/483.3 mg/483.3 mg per 14.5 mL injection
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Inmazeb 241.7 mg/241.7 mg/241.7 mg per 14.5 mL injectionIntravenous Cold chain | Regeneron Pharmaceuticals | US FDA | Available on request |
| Inmazeb 483.3 mg/483.3 mg/483.3 mg per 14.5 mL injectionIntravenous Cold chain | Regeneron Pharmaceuticals | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Inmazeb
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.